drugset / Trial / NCT00279162

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis

NCT00279162

Phase 3 Completed 160 enrolled LEO Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

Patients will receive either a gel containing both calcipotriene plus betamethasone or gel with no active ingredients as treatment for their scalp psoriasis for 8 weeks. After this time all patients will receive the gel containing both calcipotriene and betamethasone for 44 weeks. In addition, patients will receive an ointment containing both calcipotriene plus betamethasone as treatment for their psoriasis of the trunk and limbs for 52 weeks. The objective is to study the short-term efficacy of the gel, and the short and long-term safety of the gel and the ointment.

Timeline

Start
2005-12
Primary completion
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcipotriol Small molecule
Subject betamethasone dipropionate Small molecule

Indications